• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    6/24/24 4:03:43 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZIA alert in real time by email
    424B3 1 d860445d424b3.htm 424B3 424B3

    Filed Pursuant to Rule 424(b)(3)

    Registration No. 333-279773

    PROSPECTUS SUPPLEMENT

    (to Prospectus dated June 4, 2024)

    88,500,000 American Depositary Shares representing 885,000,000

    Ordinary Shares

     

    LOGO

    Kazia Therapeutics Limited

     

     

    This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-279773), with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on June 24, 2024 (the “June 24, 2024 Form 6-K”). Accordingly, we have attached the June 24, 2024 Form 6-K to this prospectus supplement.

    This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

    The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On June 21, 2024, the last reported sale price of the ADSs on Nasdaq was $0.2676 per ADS.

    Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information—D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

     

     

    The date of this prospectus supplement is June 24, 2024


     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of June, 2024

    Commission File Number 000-29962

     

     

    Kazia Therapeutics Limited

    (Translation of registrant’s name into English)

     

     

    Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     


    INFORMATION CONTAINED IN THIS FORM 6-K REPORT

    Appointment of Director

    Resignation of Principal Financial and Accounting Officer; Appointment of Principal Accounting Officer and Principal Financial Officer

    On May 16, 2024, Kazia Therapeutics Limited (the “Company”) received notice from Gabrielle Heaton of her intention to resign as the Company’s Vice President, Finance and Administration, effective June 28, 2024. Ms. Heaton’s resignation is not the result of any disagreement between Ms. Heaton and the Company, its management or board of directors, or related to the Company’s operations, policies or practices.

    On June 24, 2024, the Company’s Board of Directors appointed Jeffrey Bonacorda as its Principal Accounting Officer and Principal Financial Officer, effective July 1, 2024. Mr. Bonacorda’s annual base compensation will be $150,000.

    Mr. Bonacorda joined Kazia on May 13, 2024 and currently serves as the Company’s Vice President, Finance and Controller. Mr Bonacorda is a senior accounting professional with more than 25 years of experience in the commercial pharmaceutical, consumer products and service industries.

    The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-259224 and 333-276091).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Kazia Therapeutics Limited (Registrant)

    /s/ John Friend

    John Friend
    Chief Executive Officer
    Date: 24 June 2024
    Get the next $KZIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KZIA

    DatePrice TargetRatingAnalyst
    2/6/2025$3.00Buy
    Maxim Group
    10/14/2021$18.00Buy
    Maxim Group
    More analyst ratings

    $KZIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

    Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models a

    1/30/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

    SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. Clinical Highlights 2 of 2 evaluable patients enrolled in the Phase 1b trial achieved partial responses

    1/27/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

    SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach. "We are entering JPM Week with strong strategic and clinical momentum," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therap

    1/8/26 9:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

    2/6/25 7:53:38 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00

    10/14/21 8:02:40 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    SEC Filings

    View All

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:25:42 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:23:49 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:22:14 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Leadership Updates

    Live Leadership Updates

    View All

    KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

    SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer

    1/18/24 7:30:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

    SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "

    12/13/21 11:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

    SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin

    11/15/21 11:00:00 AM ET
    $CLRB
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/14/24 4:19:36 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kazia Therapeutics Limited

    SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/6/24 7:53:45 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    8/12/24 7:28:02 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care